Purity and identity describe the molecule. Elemental impurities and residual solvents describe the process that made it. The distinction matters because the second category varies between manufacturers producing the same compound to the same purity specification, which makes it one of the more revealing things to compare across suppliers.
Where elemental impurities come from
Metals enter through catalysts, reagents, water, and contact with equipment and container closures. They are not a property of the peptide; they are a fingerprint of the facility and the raw material supply chain.
The modern framework for them is risk-based. International Council for Harmonisation guideline Q3D, now in its second revision, sets permitted daily exposures for 24 elements and, importantly, varies those limits by route of administration, since absorption differs substantially between routes. United States Pharmacopeia chapters ⟨232⟩ and ⟨233⟩ carry the corresponding limits and the analytical procedures.
How the analysis is done
Inductively coupled plasma mass spectrometry, written ICP-MS, is the standard approach. The sample is digested, usually in acid, then introduced into an argon plasma hot enough to atomise and ionise essentially everything present. A mass spectrometer downstream counts ions by mass-to-charge ratio.
The technique reaches parts-per-billion sensitivity across most of the periodic table simultaneously, which is why it displaced the older colourimetric heavy metals test. That older method was a visual sulfide comparison, non-specific and insensitive, and a certificate still citing it is citing a superseded approach.
The four elements attracting the most attention are cadmium, lead, arsenic and mercury, grouped as the highest-concern class in the Q3D framework and expected to be assessed for every product regardless of whether they are intentionally used.
Where residual solvents come from
Peptide synthesis and purification are solvent-intensive. Material that has been through solid-phase assembly, cleavage and preparative chromatography has been in contact with several organic solvents, and drying does not necessarily remove all of them.
ICH guideline Q3C sorts solvents into three classes, and the classification is the useful part for a buyer:
- Class 1 solvents are to be avoided. Benzene and carbon tetrachloride are the recognisable examples, known or strongly suspected human carcinogens or environmental hazards.
- Class 2 solvents are limited, with specific permitted daily exposures. Several solvents common in peptide work fall here, including acetonitrile, dichloromethane, methanol and N,N-dimethylformamide.
- Class 3 solvents have low toxic potential and are controlled by good manufacturing practice rather than a specific numeric limit. Ethanol, acetic acid and ethyl acetate are in this group.
The compendial analytical procedure is United States Pharmacopeia chapter ⟨467⟩, performed by headspace gas chromatography: the sample is heated in a sealed vial, volatiles partition into the space above it, and that gas is injected onto the column.
The trifluoroacetic acid question
Trifluoroacetic acid deserves separate mention because it occupies an unusual position. It is used as an ion-pairing agent in reversed-phase purification and in the cleavage step of standard synthesis, and peptides are commonly isolated as TFA salts as a result.
That means TFA is frequently not a trace contaminant at all but a stoichiometric counterion, potentially a meaningful fraction of the vial mass. It is relevant in two ways at once: as a residual solvent question, and as part of why net peptide content differs from label weight. Where TFA content matters to the work, a buyer should ask whether a salt exchange, commonly to acetate or hydrochloride, was performed.
Why these lines are often missing
Both tests require instrumentation and method development that purity and identity do not, and neither is visible to a buyer comparing certificates casually. A supplier can present a complete-looking document covering purity, identity, sterility and endotoxin while never addressing what the process left behind.
Their presence is therefore a reasonable proxy for how seriously a supplier takes characterisation generally. Their absence is not proof of a problem, but it is an unanswered question.
What to ask for
- Is elemental impurity testing performed by ICP-MS, and against which framework's limits?
- Are the four highest-concern elements assessed for every lot or only periodically?
- Which residual solvents are monitored, and by what method?
- What counterion is the material supplied as, and is the counterion content quantified?
Why these two are grouped and why that is slightly misleading
They are grouped because both are contaminants carried over from manufacturing rather than properties of the peptide, and because both are frequently absent from research-grade panels. They are different problems with different sources and different methods.
Heavy metals arrive from reagents, catalysts and equipment. Residual solvents arrive from synthesis and purification. One is an elemental analysis and the other a chromatographic one, and a certificate reporting a single combined statement for both is reporting something vague.
When each one is worth asking for
- Heavy metals where the work is sensitive to metal contamination, including anything involving metal-dependent enzymes or trace element measurement.
- Residual solvents where material meets cells, or where an assay readout could be perturbed by an organic trace.
- Both where a supplier is new and you are establishing what their panel actually covers.
Neither is standard, and their absence is a scope decision rather than a defect. What a certificate does not test for places them alongside the other usual gaps.
What to do when neither is reported
Decide whether the work needs them, ask the supplier whether either can be added and at what cost, and record the decision either way so the gap is a documented choice rather than something nobody noticed.
This sits inside the wider picture of what gets tested and why, which why peptide testing matters sets out across the whole analytical panel.